Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 3

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Authors Elizabeth Ripley, Ari Hirsch

Published Date June 2010 Volume 2010:3 Pages 93—98

DOI http://dx.doi.org/10.2147/IJNRD.S7038

Published 28 June 2010

Elizabeth Ripley, Ari Hirsch

Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA

Abstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes.
Keywords: losartan, chronic kidney disease

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015

Electrospun fibrous scaffolds combined with nanoscale hydroxyapatite induce osteogenic differentiation of human periodontal ligament cells

Wu XN, Miao LY, Yao YF, Wu WL, Liu Y, Chen XF, Sun WB

International Journal of Nanomedicine 2014, 9:4135-4143

Published Date: 27 August 2014

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience

Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A, Seghieri G, Franconi F, Baccetti F

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:123-129

Published Date: 8 April 2013

Do calcifying nanoparticles really contain 16S rDNA?

Shiekh FA

International Journal of Nanomedicine 2012, 7:5051-5052

Published Date: 18 September 2012

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Wang W, Zhu R, Xie Q, Li A, Xiao Y, Liu H, Cui D, Chen Y, Wang S

International Journal of Nanomedicine 2012, 7:3667-3677

Published Date: 17 July 2012

Chitosan–Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study

Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN

International Journal of Nanomedicine 2012, 7:1851-1863

Published Date: 11 April 2012

Review of eprodisate for the treatment of renal disease in AA amyloidosis

Rumjon A, Coats T, Javaid MM

International Journal of Nephrology and Renovascular Disease 2012, 5:37-43

Published Date: 24 February 2012

Adhesion of osteoblasts to a nanorough titanium implant surface

Gongadze E, Kabaso DD, Bauer S, Slivnik T, Schmuki PP, van Rienen U, Iglič A

International Journal of Nanomedicine 2011, 6:1801-1816

Published Date: 31 August 2011